Pipeline

Our program involves the development of multiple complement blocker therapies with varying characteristics. Each may be effective in different subsets of inflammation induced diseases.

Our proprietary screening technology will enable us to identify the right targets in the complement mediated diseases to improve the success rate of our investment.

Our pipeline is based on the FDA approved IND and Orphan Drug Status. We are also working with FDA to get break-through status for our indications, which will further expedite our path to commercialization.